Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:

“Out in JCO the groundbreaking results (previously presented during ASCO24 by Natasha Leighl) of the randomized phase 3 trial PALOMA-3 study, which evaluated subcutaneous (SC) amivantamab combined with lazertinib in pretreated patients with EGFR-mutant NSCLC.
Remarkably, SC amivantamab, with just a 5-minute infusion time, demonstrated non-inferior efficacy and pharmacokinetics compared to intravenous (IV) administration, while reducing infusion-related reactions (IRRs) by five times.
This is a significant step forward for our patients and a revolutionary advancement in the treatment landscape for NSCLC with EGFR mutations.
Honored to have been part of this significant milestone.”

View the article attached to the post.
Source: Antonio Passaro/LinkedIn